TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19249413

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combination of Hydrochlorothiazide and Atenolol
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 800
Study: 16805723

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 0
Study: 15090706

Group type: EXPERIMENTAL
Intervention: Sauna therapy (60 degrees C far infrared-ray dry sauna for 15 minutes followed by bed rest with a blanket for 30 minutes once a day for two weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-sauna group (control)
Number of subjects: 28
Study: 11146706

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of alendronate and naproxen
Number of subjects: 26
Study: 9783096

Group type: EXPERIMENTAL
Intervention: High dose ECT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose ECT
Number of subjects: 40
Study: 8193351

Group type: EXPERIMENTAL
Intervention: Amifostine + 4-HC
Number of subjects: 15

Group type: COMPARATOR
Intervention: 4-HC alone
Number of subjects: 15
Study: 2555187

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg.h-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study: 977997

Group type: EXPERIMENTAL
Intervention: Amikacin plus cefazolin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cefazolin alone
Number of subjects: 10
Study: 31299212

Group type: EXPERIMENTAL
Intervention: Dual-task (auditory cognitive task) during adaptation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single-task during adaptation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dual-task group during de-adaptation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single-task group during de-adaptation
Number of subjects: 28
Study: 27813398

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 234

Group type: COMPARATOR
Intervention: Alendronate 70 mg/week
Number of subjects: 234
Study: 25352655

Group type: EXPERIMENTAL
Intervention: SAXA (5 mg/day) plus DAPA (10 mg/day) on background MET (≥1,500 mg/day)
Number of subjects: 534

Group type: COMPARATOR
Intervention: SAXA (5 mg/day) plus MET
Number of subjects: 534

Group type: COMPARATOR
Intervention: DAPA (10 mg/day) plus MET
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: SAXA+DAPA+MET
Number of subjects: 534

Group type: COMPARATOR
Intervention: SAXA+MET
Number of subjects: 534

Group type: COMPARATOR
Intervention: DAPA+MET
Number of subjects: 534
Study: 23530872

Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard total hip arthroplasty (THA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large-head total hip arthroplasty (THA)
Number of subjects: 0
Study: 22926844

Group type: EXPERIMENTAL
Intervention: Vitrified-warmed oocytes with an intact corona radiata
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vitrified-warmed oocytes without a corona radiata
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 6
Study: 19669251

Group type: EXPERIMENTAL
Intervention: TACE + thymalfasin (1.6 mg SC, 5 times weekly)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TACE + thymalfasin
Number of subjects: 25

Group type: COMPARATOR
Intervention: TACE only
Number of subjects: 25
Study: 17481705

Group type: EXPERIMENTAL
Intervention: High THBS-1
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: THBS-1 after adjusting for prognostic factors
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: VEGF and VEGFR-1
Number of subjects: 67
Study: 14970093

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily orally for 3 days followed by placebo for 4 days (3-day group, 93 patients)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily orally for 7 days (7-day group, 90 patients)
Number of subjects: 183
Study: 12243820

Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g in 15 mL suspension) administered rectally
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (same suspension without sucralfate) administered rectally
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Acute RTOG/EORTC toxicity of Grade 2 or greater
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rectal pain of moderate or severe grade during RT
Number of subjects: 86
Study: 9678787

Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg b.d.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: bezafibrate mono (400 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 7990255

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium plus amikacin sulfate (IPM/CS + AMK)
Number of subjects: 171
Study: 2566637

Group type: EXPERIMENTAL
Intervention: Azidothymidine therapy
Number of subjects: 41
Study: 31076415

Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Postmeal faster aspart
Number of subjects: 777

Group type: COMPARATOR
Intervention: Mealtime IAsp
Number of subjects: 777
Study: 28656141

Group type: EXPERIMENTAL
Intervention: HIT (High Intensity Training)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HIT&P (High Intensity Training with Protein Supplementation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HVHIT (High Volume/High-Intensity Training)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 120
Study: 25588784

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.2 to 0.9 mg twice daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 24014208

Group type: EXPERIMENTAL
Intervention: Sesame lignans (50 mg, sesamin/episesamin=1/1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 21613040

Group type: COMPARATOR
Intervention: No autoclaving (0 cycles)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1 autoclaving cycle
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 2 autoclaving cycles
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5 autoclaving cycles
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 10 autoclaving cycles
Number of subjects: 5
Study: 19797261

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (8 MIU)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 16861412

Group type: EXPERIMENTAL
Intervention: bupivacaine + clonidine
Number of subjects: 3

Group type: COMPARATOR
Intervention: bupivacaine + fentanyl
Number of subjects: 3

Group type: COMPARATOR
Intervention: bupivacaine + fentanyl + clonidine
Number of subjects: 3
Study: 12875806

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle (BLS) intervention that implements established recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BLS intervention that implements established recommendations plus the DASH diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice only standard of care group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle (BLS) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BLS intervention plus DASH diet
Number of subjects: 0
Study: 11832182

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy after operation in group A
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group B (no anticoagulation therapy)
Number of subjects: 71
Study: 9443614

Group type: EXPERIMENTAL
Intervention: FAN regimen: fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on days 1, 8, and 15 every 3 weeks.
Number of subjects: 38

Group type: COMPARATOR
Intervention: SUPERFAN regimen: fluorouracil 340 mg/m2 and folinic acid 200 mg/m2 on days 1-5, doxorubicin 40 mg/m2 on day 1, escalating doses of vinorelbine (15, 20, 25, 30 mg/m2) on day 1 and again on day 5 every 4 weeks.
Number of subjects: 38
Study: 8251276

Group type: EXPERIMENTAL
Intervention: i.v. clonidine 150 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: extradural clonidine 150 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: clonidine (both routes)
Number of subjects: 10
Study: 3953330

Group type: EXPERIMENTAL
Intervention: Treatment prescribed to 52 incontinent residents
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group of 30 incontinent residents
Number of subjects: 82
Study: 30869167

Group type: EXPERIMENTAL
Intervention: Perampanel 2-12 mg/day
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study: 29516701

Group type: EXPERIMENTAL
Intervention: Intradermal needle‐embedding therapy (once every other day for 20 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional medicines, neuromuscular electrical stimulation of the bilateral midlines of the neck and swallowing function training
Number of subjects: 80
Study: 24890422

Group type: EXPERIMENTAL
Intervention: High negative pressure (HNP) suction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal negative pressure (NNP) suction
Number of subjects: 90
Study: 22700533

Group type: EXPERIMENTAL
Intervention: Very Early Mobilization (VEM) within 24 hours of admittance
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mobilization between 24 and 48 hours (Control)
Number of subjects: 56
Study: 20926998

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) and isokinetic muscular strengthening exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isokinetic exercises only (Control)
Number of subjects: 40
Study: 17703315

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 11
Study: 15237766

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Salmeterol (84 microg/d)
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 1473
Study: 12243439

Group type: EXPERIMENTAL
Intervention: Sweep gas flow at 1.60 l/min/m2 (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sweep gas flow at 2.0 l/min/m2 (Group 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sweep gas flow at 1.35 l/min/m2 (Group 1)
Number of subjects: 30
Study: 9792386

Group type: EXPERIMENTAL
Intervention: Male/Female condom group
Number of subjects: 504

Group type: COMPARATOR
Intervention: Male condom group
Number of subjects: 504
Study: 7634883

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6'WT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prediction equation from group A: VO2 max = 0.006 x distance (feet) + 3.38
Number of subjects: 60
Study: 2152844

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d) and cholecalciferol (25 micrograms/d) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 417361

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Piracetam 9.6 g/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31939395

Group type: EXPERIMENTAL
Intervention: Holder method of pasteurization
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flash method of pasteurization
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control sample (before pasteurization)
Number of subjects: 48
Study: 27651506

Group type: EXPERIMENTAL
Intervention: Crushed intranasal Morphine ARER
Number of subjects: 25

Group type: COMPARATOR
Intervention: Crushed intranasal ER morphine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intact Morphine ARER
Number of subjects: 25
Study: 25546166

Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fed state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet administered in fasted state
Number of subjects: 0
Study: 24028593

Group type: EXPERIMENTAL
Intervention: Tooth-borne distractor (Hyrax)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bone-borne distractor (transpalatal distractor - TPD)
Number of subjects: 32
Study: 21237212

Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administered 1h before exercise (45 min, 2 W/kg of lean body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Exercise without Acipimox
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administered 1h before exercise
Number of subjects: 14
Study: 19217443

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic (H-E) clamp with porcine or human insulin (40 mU/[m(2) min])
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: First clamp
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Second clamp
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic (H-E) clamp
Number of subjects: 10

Group type: COMPARATOR
Intervention: Porcine vs human insulin
Number of subjects: 10
Study: 15784036

Group type: EXPERIMENTAL
Intervention: Octreotide 300 mug, b.i.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Octreotide 300 mug, b.i.d. plus midodrine 7.5 mg, t.i.d.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 25
Study: 11915786

Group type: COMPARATOR
Intervention: 0.9% saline (Group C)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ephedrine 6 mg (Group E‐6)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ephedrine 12 mg (Group E‐12)
Number of subjects: 68
Study: 10320260

Group type: EXPERIMENTAL
Intervention: Lidocaine (standard antiarrhythmic dose)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 65
Study: 7722706

Group type: EXPERIMENTAL
Intervention: Atole (high protein and energy supplement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresco (beverage with no protein and little energy)
Number of subjects: 0
Study: 1779513

Group type: EXPERIMENTAL
Intervention: Corinfar (20 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hypothiazide (50 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anapriline (80 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 7240596

Group type: EXPERIMENTAL
Intervention: Urushiol oil injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 0
Study: 30074122

Group type: EXPERIMENTAL
Intervention: Theory of Mind training
Number of subjects: 135

Group type: COMPARATOR
Intervention: Waitlist group (Control)
Number of subjects: 135
Study: 28864284

Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesics (300 mg acetaminophen and 20 mg caffeine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Codeine-containing analgesics (300 mg acetaminophen and 20 mg codeine)
Number of subjects: 80
Study: 25261399

Group type: EXPERIMENTAL
Intervention: 0.4 % stannous fluoride gel and a crème containing 10 % CPP‐ACP applied three times daily and fluoride gel once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Similar crème without CPP‐ACP applied three times daily and fluoride gel once daily
Number of subjects: 24
Study: 24293993

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21793389

Group type: EXPERIMENTAL
Intervention: EA‐5 Hz
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EA‐50 Hz
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EA‐100 Hz
Number of subjects: 120
Study: 19300039

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: (89)Sr chloride
Number of subjects: 130

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 130

Group type: COMPARATOR
Intervention: (153)Sm
Number of subjects: 130
Study: 17498610

Group type: EXPERIMENTAL
Intervention: OSIS (One Step Incontinence System)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BW (Box of Wipes)
Number of subjects: 24
Study: 15026896

Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy
Number of subjects: 37
Study: 11603873

Group type: EXPERIMENTAL
Intervention: Home Study Module (HSM) in addition to regular teaching of clinical breast examination
Number of subjects: 136

Group type: COMPARATOR
Intervention: Regular teaching alone (Control)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Home Study Module (HSM)
Number of subjects: 136
Study: 9673532

Group type: EXPERIMENTAL
Intervention: L-carnitine treatment (20 mg/kg intravenously at the end of each hemodialysis session)
Number of subjects: 10
Study: 8033496

Group type: EXPERIMENTAL
Intervention: DuP 128 (900 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DuP 128 (1800 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DuP 128 (3600 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neomycin (1 gm twice a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DuP 128
Number of subjects: 30
Study: 2686331

Group type: EXPERIMENTAL
Intervention: Octreotide 400 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Octreotide 50 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Octreotide 200 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 1092282

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride with marital therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride with minimal contact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with marital therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with minimal contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0
Study: 30741469

Group type: EXPERIMENTAL
Intervention: Maxillary implant overdentures on solitary attachments (group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maxillary implant overdentures on bars (group II)
Number of subjects: 50
Study: 28011037

Group type: EXPERIMENTAL
Intervention: Lumacaftor 400 mg every 12 h / Ivacaftor 250 mg every 12 h
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Lumacaftor/ivacaftor-treated patients
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Lumacaftor 600 mg once daily / Ivacaftor 250 mg every 12 h
Number of subjects: 1030
Study: 25251040

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both self-ligating and conventional brackets
Number of subjects: 8
Study: 24092568

Group type: EXPERIMENTAL
Intervention: Scopolamine detoxification technique (SDT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard methadone detoxification (MD)
Number of subjects: 91
Study: 21654350

Group type: EXPERIMENTAL
Intervention: 400 mg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 200 mg 4 times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 27
Study: 18093100

Group type: EXPERIMENTAL
Intervention: 5 French guiding catheters
Number of subjects: 90

Group type: COMPARATOR
Intervention: 7 French guiding catheters
Number of subjects: 90
Study: 17178957

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g IV)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (3 g IV)
Number of subjects: 418
Study: 12753318

Group type: EXPERIMENTAL
Intervention: Pamidronate (0.5 mg/kg) given at the time of transplantation and 1 month later
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10618584

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan (ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitor alone (captopril)
Number of subjects: 0
Study: 8906027

Group type: EXPERIMENTAL
Intervention: Optic nerve sheath decompression surgery
Number of subjects: 420

Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 420
Study: 2068472

Group type: EXPERIMENTAL
Intervention: Aztreonam plus clindamycin
Number of subjects: 316

Group type: COMPARATOR
Intervention: Tobramycin plus clindamycin
Number of subjects: 316
Study: 6631616

Group type: EXPERIMENTAL
Intervention: interactive computer interview
Number of subjects: 108

Group type: COMPARATOR
Intervention: face-to-face interview
Number of subjects: 108

Group type: COMPARATOR
Intervention: self-administered questionnaire
Number of subjects: 108
Study: 30109552

Group type: EXPERIMENTAL
Intervention: US-TAPb (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No US-TAPb (group B)
Number of subjects: 100
Study: 27659044

Group type: EXPERIMENTAL
Intervention: Ultracongruent (UC) TKA
Number of subjects: 127

Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) TKA
Number of subjects: 127
Study: 25209052

Group type: EXPERIMENTAL
Intervention: Multi-component school based intervention
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2348
Study: 25090856

Group type: EXPERIMENTAL
Intervention: Double gloves
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 303
Study: 23032478

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 19427625

Group type: EXPERIMENTAL
Intervention: PVB with GA
Number of subjects: 80
Study: 17697141

Group type: EXPERIMENTAL
Intervention: Low doses of aspirin
Number of subjects: 82